Eribulin

Generic Name: Eribulin

Brand Names: Halaven, Eribulin Baxter, Mevlyq

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₉NO_₁₁

CAS Number: 253128-41-5

Unique Ingredient Identifier: LR24G6354G

Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .

Indication: For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions: Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma

Clinical Trials

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Eribulin

First Posted Date: 2014-08-13

Last Posted Date: 2016-04-15

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT02215876

Locations: 🇸🇬
Johns Hopkins Singapore, Singapore, Singapore

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Metastatic Ureter Carcinoma
Metastatic Urethral Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Stage III Ureter Cancer AJCC v7
Stage III Urethral Cancer AJCC v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
Stage IV Ureter Cancer AJCC v7
Stage IV Urethral Cancer AJCC v7
Ureter Urothelial Carcinoma
Urethral Urothelial Carcinoma

Interventions: Drug: Eribulin Mesylate
Drug: Gemcitabine Hydrochloride

First Posted Date: 2014-06-30

Last Posted Date: 2019-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT02178241

Locations: 🇺🇸
UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 15 locations

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

Phase 1

Completed

Conditions: Pediatrics
Solid Tumors

Interventions: Drug: Eribulin Mesylate

First Posted Date: 2014-06-24

Last Posted Date: 2019-01-15

Lead Sponsor: Eisai Inc.

Target Recruit Count: 23

Registration Number: NCT02171260

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 15 locations

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1

Completed

Conditions: HER2/Neu Negative
Estrogen Receptor Negative
Triple-negative Breast Carcinoma
Progesterone Receptor-negative
Stage IV Breast Cancer

Interventions: Drug: everolimus
Drug: eribulin mesylate
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-04-22

Last Posted Date: 2022-07-05

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 27

Registration Number: NCT02120469

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States
🇺🇸
South Pasadena Cancer Center, South Pasadena, California, United States

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Phase 2

Completed

Conditions: Recurrent Osteosarcoma

Interventions: Drug: Eribulin Mesylate
Other: Pharmacological Study

First Posted Date: 2014-03-27

Last Posted Date: 2020-05-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT02097238

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 116 locations

Study of Eribulin in Children With Cancer to Determine Safety

Phase 1

Terminated

Conditions: Pediatric Cancer
Solid Tumors
Lymphoma

Interventions: Drug: Eribulin mesylate

First Posted Date: 2014-03-10

Last Posted Date: 2020-03-10

Lead Sponsor: University of Oklahoma

Target Recruit Count: 3

Registration Number: NCT02082626

Locations: 🇺🇸
Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States

Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

Phase 2

Completed

Conditions: Breast Neoplasm
Metastasis

Interventions: Drug: Eribulina

First Posted Date: 2014-02-12

Last Posted Date: 2020-11-27

Lead Sponsor: MedSIR

Target Recruit Count: 53

Registration Number: NCT02061085

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Phase 3

Suspended

Conditions: Invasive Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7
HER2/Neu Negative
Breast Adenocarcinoma
Stage IIIC Breast Cancer AJCC v7

Interventions: Drug: Eribulin Mesylate
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2014-01-16

Last Posted Date: 2024-08-20

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 201

Registration Number: NCT02037529

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
🇺🇸
Essentia Health NCI Community Oncology Research Program, Duluth, Minnesota, United States

and more 36 locations

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Phase 2

Completed

Conditions: HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
HER2-negative Circulating Tumor Cells
Postmenopausal Female Patients

Interventions: Drug: Eribulin
Drug: Ribociclib

First Posted Date: 2014-01-14

Last Posted Date: 2024-06-04

Lead Sponsor: Prof. Wolfgang Janni

Target Recruit Count: 116

Registration Number: NCT02035813

Locations: 🇩🇪
University Hospital Ulm -Department of Gynecology, Ulm, Baden-Württemberg, Germany

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer
Breast Neoplasms

Interventions: Drug: Eribulin mesylate

First Posted Date: 2013-10-11

Last Posted Date: 2016-10-07

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 101

Registration Number: NCT01961544

Locations: 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷
Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy